<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864318</url>
  </required_header>
  <id_info>
    <org_study_id>08 GENH 06</org_study_id>
    <nct_id>NCT00864318</nct_id>
  </id_info>
  <brief_title>Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis</brief_title>
  <acronym>TICE</acronym>
  <official_title>Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Not randomized, multicentric, national phase II trial estimating the efficacy of an
      intensification protocol in patients with refractory germ cell tumors with relapse and bad
      prognosis.

      Treatment consists in two Paclitaxel and Ifosfamide intensification cycles followed by three
      Carboplatine and Etoposide high dose cycles. The point is the individual Carboplatine
      adjustment to take into account inter-individual patients variability.

      This adaptation allow to control each patient plasmatic exposition to avoid both inacceptable
      toxicities (such as ear toxicity) and a low exposition losing then the benefit of this high
      dose protocol.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 13, 2009</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate(by chemotherapy or chemotherapy + surgery), pathological complete response rate.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To find a predictive value for Cystatin C as a biomarker of renal function to avoid next to follow plasmatic concentrations to adapt Carboplatine dose in TICE protocol.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Etoposide pharmacokinetics (in particular inter-individual variability of Etoposide plasmatic concentrations AUC in such patients</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphisms involved in response and safety treatments</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">101</enrollment>
  <condition>Germ Cell Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles</description>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles</description>
    <other_name>Holoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatine</intervention_name>
    <description>From cycle 3 to cycle 5 :
Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3</description>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytapheresis + transfusion of autologous peripheral blood stem cells</intervention_name>
    <description>Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.
At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Germ cell tumors whatever histology (TGNS or séminoma : TGS ) whose origin is gonadic,
             extra-gonadic, retro-peritoneal or primitive mediastinal

          2. Age &gt;= 18 years old

          3. Histologically confirmed germ cell tumor (TGS) or biomarkers rate allowing to diagnose
             germ cell tumor without histology (TGNS)

          4. Relapse or progression with bad prognosis in 1st treatment line : One of these
             criteria valid point 4 :

             progression after incomplete clinical response (Stable disease) to a Cisplatin basis
             chemotherapy; biomarker progression 4 weeks following the last chemotherapy cycle
             administration; progression during the first treatment line without obtention of at
             least stable disease; primitive mediastinal origin in first relapse.

          5. TGNS or TGS in relapse after 2 treatment lines

          6. Disease progression ( previous points 4 or 5) documented by :

             tumors biomarkers increase (AFP and/or HCG) if no, a biopsy is needed to confirm
             presence of tumors active cells

          7. ECOG Performance status 0-2

          8. Biological Function :

             Neutrophils &gt;= 1500/mm3, Platelets &gt;= 150.000/mm3 ; normal creatinine (or clearance &gt;=
             50 ml/mn) ; SGOT, SGPT &lt;= 2,5N (or 5N if hepatic metastases), Bilirubin &lt; 1,5N

          9. Cardiac Functions (FEV &gt;= 50%), Respiratory Functions , neurological Functions
             compatibles with high dose chemotherapy administration

         10. Absence of previous intensification

         11. Patient Information and Informed consent signature

         12. HIV and B and C hepatitis negative serologies

         13. Negative pregnancy test for women with reproductive potential and adequate
             contraception before study entry

         14. Patient affiliated to social security system

        Exclusion Criteria:

          1. Patients whose diagnosis of relapse was not confirmed by an anatomopathological
             examination or by an increase of tumors markers

          2. Primitive encephalic germ cell tumors

          3. Germ cell tumors in relapse with favorable factors of treatment response to
             conventional chemotherapy (RC sustainable after Cisplatin): prior cRC or incomplete
             clinical response but with normalization of markers and testicular origin

          4. Growing Teratoma lesions

          5. Patients with HIV infection, hepatitis B and C

          6. Patients with symptomatic brain metastases despite appropriate corticosteroid
             treatment

          7. Associated pathology may prevent the patient to receive treatment, creatinine
             clearance ≤ 50 mL / min (calculated by Cockcroft-Gault)

          8. FEV &lt;50%

          9. History of cancer (except basal cell epithelioma skin cancer) in the 3 years preceding
             the entry into the trial

         10. Patient already included in another clinical trial involving an experimental molecule

         11. Pregnant or breast feeding women

         12. Persons without liberty or under guardianship,

         13. Geographical, social or psychological conditions that do not permit compliance with
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine CHEVREAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Val d'aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06050</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital TENON</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory</keyword>
  <keyword>germ cell tumors</keyword>
  <keyword>relapse</keyword>
  <keyword>bad prognosis</keyword>
  <keyword>Refractory germ cell tumors with relapse and bad prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

